ClinConnect ClinConnect Logo
Search / Trial NCT06178575

Apply Machine Learning to the Interpretation of Urinary Crystal Morphology.

Launched by YI-SHIOU TSENG · Dec 12, 2023

Trial Information

Current as of July 22, 2025

Not yet recruiting

Keywords

Machine Learning Urinary Crystal

ClinConnect Summary

This clinical trial is studying a new way to analyze crystals found in urine, which can help diagnose kidney stones (also known as kidney calculi). Researchers are developing a special software that uses artificial intelligence (AI) to look at images of urine crystals and quickly identify their types and sizes. The goal is to make this process faster, more accurate, and easier for healthcare professionals, allowing them to get results in real-time when they input these images.

Currently, the trial is not recruiting participants, and it will analyze images from a previous study. There are no specific exclusions for participants, which means anyone’s images from that study can be included. If you are part of this previous study, your urine crystal images may contribute to helping create this technology, ultimately improving how kidney stones are diagnosed and treated.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Retrospectively analyze the urine crystal images preserved from the previous study 107123-E for crystal type analysis. Subsequently, conduct image preprocessing and label categorization for machine software learning and inference. The interpreted results will then be assessed for accuracy using statistical analysis software.
  • Exclusion Criteria:
  • Not applicable

About Yi Shiou Tseng

Yi-Shiou Tseng is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative therapeutic solutions. With a focus on rigorous scientific methodologies and ethical standards, the organization collaborates with leading researchers and institutions to conduct clinical trials that address unmet medical needs. Yi-Shiou Tseng emphasizes transparency, integrity, and patient safety in all its initiatives, striving to contribute valuable insights to the medical community and enhance the development of effective treatments.

Locations

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported